Allergan Nasal Spray For Frequent Nighttime Urination Faces Review Hurdles
Executive Summary
Advisory committee will weigh in on desmopressin as FDA questions broad indication and says clinical meaningfulness of treatment effects for Serenity Pharmaceuticals/Allergan’s product vs. placebo are unclear.
You may also be interested in...
Desmopressin Battle: Ferring Asks FDA To Reject Serenity's Nocturia Drug
Serenity's SER120 should be held to the same efficacy standards as Ferring's Nocdurna, which the agency has declined to approve three times, citizen petition says.
Allergan’s Nasal Spray For Frequent Nighttime Urination Gets Cautious Panel Nod
Desmopressin's limited efficacy over placebo doesn't dissuade FDA's advisory committee, which votes 14 to 4 in favor of approval even as many suggest indication be narrowed.
Ferring’s Nocdurna Nixed By FDA Panel, But Gets Multiple Paths Forward
Advisory committee members recommend Ferring conduct new pre-approval study to demonstrate clinical meaningful benefit of nocturia treatment, offering up variety of possible study designs.